The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis
- PMID: 12694816
- DOI: 10.1016/s0014-2999(03)01570-x
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis
Abstract
This study evaluated the effects of the adenosine A(3) receptor agonist, N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA), in two murine models of colitis, the dextran sodium sulphate-induced colitis and the spontaneous colitis found in interleukin-10 gene deficient mice. IB-MECA was given orally twice a day at a dose of either 1 or 3 mg/kg/day. Evaluation of colon damage and inflammation was determined grossly (body weight, rectal bleeding) and biochemically (colon levels of myeloperoxidase, malondialdehyde, chemokines and cytokines). There was significantly increased inflammatory cell infiltration into the colon associated with an increase in colon levels of cytokines and chemokines; with subsequent free radical related damage in both dextran sodium sulphate-induced colitis and 10-week-old interleukin-10(-/-) mice. IB-MECA protected in both models against the colitis induced inflammatory cell infiltration and damage and attenuated the increases in colon inflammatory cytokine and chemokine levels. Thus activation of the adenosine A(3) receptor is effective in protecting against colitis.
Similar articles
-
An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway.Sci Rep. 2015 Mar 12;5:9047. doi: 10.1038/srep09047. Sci Rep. 2015. PMID: 25762375 Free PMC article.
-
The adenosine A2A receptor agonist CGS 21680 fails to ameliorate the course of dextran sulphate-induced colitis in mice.Inflamm Res. 2007 May;56(5):204-9. doi: 10.1007/s00011-006-6150-7. Inflamm Res. 2007. PMID: 17588136 Free PMC article.
-
A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA.Eur J Pharmacol. 2002 Dec 13;457(1):57-69. doi: 10.1016/s0014-2999(02)02645-6. Eur J Pharmacol. 2002. PMID: 12460644
-
An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice.Eur J Pharmacol. 1998 Oct 9;358(3):261-8. doi: 10.1016/s0014-2999(98)00619-0. Eur J Pharmacol. 1998. PMID: 9822893
-
Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists.Br J Pharmacol. 1998 Sep;125(2):379-87. doi: 10.1038/sj.bjp.0702040. Br J Pharmacol. 1998. PMID: 9786512 Free PMC article.
Cited by
-
The role of purinergic signaling in acupuncture-mediated relief of neuropathic and inflammatory pain.Purinergic Signal. 2024 Feb 2. doi: 10.1007/s11302-024-09985-y. Online ahead of print. Purinergic Signal. 2024. PMID: 38305986 Review.
-
CD73-generated extracellular adenosine promotes resolution of neutrophil-mediated tissue injury and restrains metaplasia in pancreatitis.FASEB J. 2023 Jan;37(1):e22684. doi: 10.1096/fj.202201537R. FASEB J. 2023. PMID: 36468677 Free PMC article.
-
Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.Immunopharmacol Immunotoxicol. 2021 Dec;43(6):633-643. doi: 10.1080/08923973.2021.1988102. Epub 2021 Oct 14. Immunopharmacol Immunotoxicol. 2021. PMID: 34647511 Free PMC article. Review.
-
Adenosine and Inflammation: Here, There and Everywhere.Int J Mol Sci. 2021 Jul 19;22(14):7685. doi: 10.3390/ijms22147685. Int J Mol Sci. 2021. PMID: 34299305 Free PMC article. Review.
-
Microbial and genetic-based framework identifies drug targets in inflammatory bowel disease.Theranostics. 2021 Jun 1;11(15):7491-7506. doi: 10.7150/thno.59196. eCollection 2021. Theranostics. 2021. PMID: 34158863 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials